Decitabine and Cedazuridine · Inqovi, ASTX727

What is Decitabine and Cedazuridine?

INQOVI is an oral combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor. Decitabine incorporates into DNA and inhibits DNA methyltransferase, causing hypomethylation and cellular differentiation or apoptosis. Cedazuridine prevents decitabine degradation, increasing its bioavailability.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Inqovi, ASTX727

Drug type

Small molecule

Targets

DNA methyltransferase, Cytidine deaminase (CDA)

Mechanism

Inhibitor of DNA methyltransferase and Cytidine deaminase (CDA)

Pathways

DNA methylation, apoptosis, cellular differentiation

Therapy area

Oncology

Developer

Taiho Pharmaceutical Co., Ltd.

In trials of

SNDX

FDA status

Approved as Inqovi, NDA212576 · FDA label

✅ FDA-approved uses

• Myelodysplastic syndromes
• Chronic myelomonocytic leukemia
• Acute myeloid leukemia

From the indications section of the FDA label (version of May 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia

Sources

• FDA label (DailyMed)
• FDA label Inqovi (2026-05-25), indications
• NCI Thesaurus

Updated Oct 3, 2026.